Product and trial design considerations on the path towards a vaccine to combat opioid overdose

Product and trial design considerations on the path towards a vaccine to combat opioid overdose

Abstract Opioid overdose deaths are an evolving public health emergency in the United States. Recent advancements in drug conjugate vaccine design and adjuvantation technologies have re-ignited interest in the potential clinical utility of opioid vaccination. Here we present the concept of fentanyl...

Full description

Saved in:
Bibliographic Details
Main Authors: Asimenia Angelidou, Jacob A. Koster, Amy C. Sherman, Caitlyn McLoughlin, Pooja Lalwani, Aisling Kelly, Ahsan Saeed, Kerry McEnaney, Lindsey R. Baden, Melissa Brogna, Elissa R. Weitzman, Sharon Levy, David J. Dowling, Ofer Levy
Format: Article
Language:English
Published: Nature Portfolio 2025-02-01
Series:npj Vaccines
Online Access:https://doi.org/10.1038/s41541-025-01083-3
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Opioid overdose deaths are an evolving public health emergency in the United States. Recent advancements in drug conjugate vaccine design and adjuvantation technologies have re-ignited interest in the potential clinical utility of opioid vaccination. Here we present the concept of fentanyl vaccination as a complementary strategy for opioid overdose prevention with a focus on vaccine safety, efficacy, and considerations for vaccine development and testing in early phase human clinical trials.
ISSN:2059-0105

Similar Items